Stevenage Bioscience Catalyst (SBC) is a not-for-profit science park formed in 2012 through a collaboration between Government, GlaxoSmithKline, Wellcome and Innovate UK.

Our vision is to accelerate the translation of cutting-edge science to improve the health and quality of people’s lives. We are home to over 45 businesses that specialise in the development of treatments for human diseases.

Located in Stevenage, at the centre of a world-leading cell and gene therapy cluster, SBC offers 1.6mn sq ft of lettable space and development pipeline. Businesses based at SBC have collectively raised over £3.6bn in funding since it opened in 2012. This puts Stevenage at parity with Cambridge, London and Oxford in terms of equity raised on biotechnology (2017-2020). The Campus was awarded Life Sciences Opportunity Zone and High Potential Opportunity status by the UK Government in 2020.

Our ecosystem of business and scientific support enables organisations to connect and grow. The ’Lab Hotel’ facility provides early-stage start-ups with rent-free office and lab space for six months. Young companies are also given free access to shared specialist equipment, mentors, grant specialists and investors. Our accelerator programmes, such as Catalyser, help therapeutics and tech-bio companies refine their commercialisation strategies, deliver innovation to market and scale. Wrapped around this is a collaborative and inclusive environment. We offer a calendar of networking events, roundtables and social activities designed to help businesses thrive as part of a vibrant science community.

Find out more about SBC from CEO Dr Sally Ann Forsyth OBE, in our video below.